| Home > In process > S1-Handlungsempfehlung der Deutschen Gesellschaft für Nuklearmedizin zur Durchführung von Hirnperfusions-SPECT-Untersuchungen mit 99mTc-markierten Radiopharmaka (Stand 09/2025). |
| Journal Article | DZNE-2026-01044 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2026
Thieme
Stuttgart
This record in other databases:
Please use a persistent id in citations: doi:10.1055/a-2821-9573
Abstract: This procedure guideline for brain perfusion SPECT is intended to support the planning, execution, quality control, evaluation and reporting of brain perfusion SPECT studies using the 99 mTc-labelled radiopharmaceuticals [99 mTc]Tc-HMPAO and [99 mTc]Tc-ECD. It is an update and expansion built on the 2019 version of the procedure guideline. It was developed through an informal process as a consensus of the Neuroimaging Working Group of the German Society of Nuclear Medicine. It is intended for use by physicians and physical-technical staff (technologists, physicists) working in nuclear medicine.
Keyword(s): Tomography, Emission-Computed, Single-Photon: methods (MeSH) ; Tomography, Emission-Computed, Single-Photon: standards (MeSH) ; Radiopharmaceuticals (MeSH) ; Nuclear Medicine: standards (MeSH) ; Humans (MeSH) ; Germany (MeSH) ; Perfusion Imaging: standards (MeSH) ; Brain: diagnostic imaging (MeSH) ; Brain: blood supply (MeSH) ; Societies, Medical (MeSH) ; Organotechnetium Compounds (MeSH) ; Technetium (MeSH) ; Radiopharmaceuticals ; Organotechnetium Compounds ; Technetium
|
The record appears in these collections: |